Search results
Results from the WOW.Com Content Network
The structure of paclitaxel, a widely used mitotic inhibitor. A mitotic inhibitor, microtubule inhibitor, or tubulin inhibitor, is a drug that inhibits mitosis, or cell division, and is used in treating cancer, gout, and nail fungus. These drugs disrupt microtubules, which are structures that pull the chromosomes apart when a cell divides.
Early Mitotic Inhibitor 1 (EMI1) is an important cell cycle regulator which ensures timely mitotic entry by primarily inhibiting Anaphase-Promoting Complex/Cyclosome (APC/C) activity. This protein is present in many organisms including Xenopus, Zebrafish, Drosophila (homologous protein: Rca1), and Humans (also often known as F-box only protein ...
Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.
The discovery of the Wee1 gene is accredited to Paul Nurse, who first identified it in fission yeast (Schizosaccharomyces pombe) in 1978. In his initial experiments, Nurse demonstrated Wee1 to be a negative regulator of mitosis, such that Wee1+ activity was critical in preventing premature mitosis in Cdc25+ (a mitotic inducer) yeast cells and increased Wee1+ expression could further delay cell ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Mitotic inhibitors (32 P) Pages in category "Mitosis" The following 42 pages are in this category, out of 42 total. This list may not reflect recent changes. ...
The protein encoded by this gene belongs to the Fbxs class. This protein is similar to xenopus early mitotic inhibitor-1 (Emi1), which is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. [7] Moreover, Emi1 also assembles a CRL1 complex that targets RAD51 for ubiquitin-mediated degradation. [8]
Aurora B inhibitors, which are also in clinical development lead to abnormal kinetochore to microtubule attachment and abrogate the mitotic checkpoint as well. [81] Survivin is also an attractive molecular target for clinical therapeutic development as it acts as a major node in a multitude of pathways, one of which is spindle formation and ...